v3.25.4
Organization - Schedule of Error Corrections and Prior Period Adjustments (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Error Corrections and Prior Period Adjustments Restatement [Line Items]      
Selling, general and administrative expense $ 314,026 $ 343,798 $ 303,879
Research and development expense 12,113 13,951 13,446
Operating income (loss) 53,975 (15,195) (81,725)
Income (loss) before income taxes 25,709 (52,342) (121,111)
Net income (loss) from continuing operations 27,274 (47,049) (195,625)
Loss attributable to noncontrolling interest   10,924  
Net loss attributable to Bioventus Inc. 22,732 (36,125) (156,230)
Comprehensive loss 28,110 (51,230) (194,493)
Comprehensive loss attributable to noncontrolling interest (4,705) 11,738 24,230
Comprehensive loss attributable to Bioventus Inc. $ 23,405 $ (39,492) $ (155,326)
Diluted (in dollars per share) $ 0.33 $ (0.56) $ (2.49)
Basic (in dollars per share) $ 0.34 $ (0.56) $ (2.49)
Additional paid-in capital $ 520,851 $ 508,092  
Accumulated deficit $ (334,929) (357,661)  
As Previously Reported      
Error Corrections and Prior Period Adjustments Restatement [Line Items]      
Selling, general and administrative expense   340,894  
Research and development expense   13,639  
Operating income (loss)   (11,979)  
Income (loss) before income taxes   (49,126)  
Net income (loss) from continuing operations   (43,833)  
Loss attributable to noncontrolling interest   10,291  
Net loss attributable to Bioventus Inc.   (33,542)  
Comprehensive loss   (48,014)  
Comprehensive loss attributable to noncontrolling interest   11,105  
Comprehensive loss attributable to Bioventus Inc.   $ (36,909)  
Diluted (in dollars per share)   $ (0.52)  
Basic (in dollars per share)   $ (0.52)  
Additional paid-in capital   $ 505,509  
Accumulated deficit   (355,078)  
Adjustments      
Error Corrections and Prior Period Adjustments Restatement [Line Items]      
Selling, general and administrative expense   2,904  
Research and development expense   312  
Operating income (loss)   (3,216)  
Income (loss) before income taxes   (3,216)  
Net income (loss) from continuing operations   (3,216)  
Loss attributable to noncontrolling interest   633  
Net loss attributable to Bioventus Inc.   (2,583)  
Comprehensive loss   (3,216)  
Comprehensive loss attributable to noncontrolling interest   633  
Comprehensive loss attributable to Bioventus Inc.   $ (2,583)  
Diluted (in dollars per share)   $ (0.04)  
Basic (in dollars per share)   $ (0.04)  
Additional paid-in capital   $ 2,583  
Accumulated deficit   $ (2,583)